article thumbnail

STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds

STAT

Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, and the findings raise questions about the extent to which industry influence may have led to patient harm, according to a new study.

article thumbnail

STAT+: Pharmalittle: We’re reading about Sanders’ pharma pressure campaign, AstraZeneca’s new ADC factory, and more

STAT

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies before the panel with ambitious demands related to their pricing. Bernie Sanders is figuring out just how far bullying drugmakers can take him , STAT writes. Sanders (I-Vt.) AstraZeneca is investing $1.5

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Responsible antibiotic use: How the industry can lead the way for evidence-backed guidelines

Express Pharma

Antibiotics have long been essential in treating common infections and supporting complex medical interventions like surgeries, cancer chemotherapy, and organ transplants. This creates little financial incentive for pharmaceutical companies to invest in antibiotic research.

article thumbnail

Janssen rebrands its identity

European Pharmaceutical Review

The Janssen Pharmaceutical Companies of Johnson & Johnson has changed its name to Johnson & Johnson Innovative Medicine (J&J Innovative Medicine). Branding innovation in the pharmaceutical industry This week, Novartis has also finalised changes to its divisions.

article thumbnail

NICE recommends innovative breast cancer drug

European Pharmaceutical Review

An important advance in treating breast cancer The pharmaceutical company shared that its oral small molecule poly (ADP-ribose) polymerase (PARP) inhibitor is indicated in adults who have had an anthracycline or a taxane, or both, if suitable, and endocrine therapy in patients with hormone receptor (HR)-positive breast cancer, if suitable.

article thumbnail

Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030

Express Pharma

Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate cancer. Pluvicto is indicated for metastatic CRPC (mCRPC) patients previously treated with ADT and taxane chemotherapy. billion by 2030, far outshining Xofigo.

article thumbnail

Chemo-free regimen demonstrates efficacy in NSCLC

European Pharmaceutical Review

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).